(E)-5,6-difluoro-2-(hydroxyimino)-2,3-dihydro-1H-inden-1-one | 1008361-85-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (E)-5,6-difluoro-2-(hydroxyimino)-2,3-dihydro-1H-inden-1-one
• 英文别名: 5,6-difluoroindan-1,2-dione 2-oxime；(2E)-5,6-difluoro-1H-indene-1,2(3H)-dione 2-oxime；1H-Indene-1,2(3H)-dione-5,6-difluoro-2-oxime；(2E)-5,6-difluoro-2-hydroxyimino-3H-inden-1-one
• CAS: 1008361-85-0
• 化学式: C₉H₅F₂NO₂
• 分子量: 197.141
• InChiKey: BYYGMUGRXMVSNS-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-5,6-difluoro-2-(hydroxyimino)-2,3-dihydro-1H-inden-1-one 在 palladium 10% on activated carbon 氢气 作用下， 以 溶剂黄146 为溶剂， 反应 72.0h， 生成 2-amino-5,6-difluoroindan-1-one
  参考文献：
  名称：

  WO2008/142454

  摘要：

  公开号：
• 作为产物：
  描述：

  3-(3,4-二氟苯基)丙酸 在 氯磺酸 、 乙酰氯 、 亚硝酸异戊酯 作用下， 以 甲醇 、 正庚烷 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (E)-5,6-difluoro-2-(hydroxyimino)-2,3-dihydro-1H-inden-1-one
  参考文献：
  名称：

  Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity

  摘要：

  Malaria persists as one of the most devastating global infectious diseases. The pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH) has been identified as a new malaria drug target, and a triazolopyrimidine-based DHODH inhibitor I (DSM265) is in clinical development. We sought to identify compounds with higher potency against Plasmodium DHODH while showing greater selectivity toward animal DHODHs. Herein we describe a series of novel triazolopyrimidines wherein the p-SF5-aniline was replaced with substituted 1,2,3,4-tetrahydro-2-naphthyl or 2-indanyl amines. These compounds showed strong species selectivity, and several highly potent tetrahydro-2-naphthyl derivatives were identified. Compounds with halogen substitutions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. falciparum SCID mouse malaria model. These data suggest that tetrahydro-2-naphthyl derivatives have the potential to be efficacious for the treatment of malaria, but due to higher metabolic clearance than 1, they most likely would need to be part of a multidose regimen.

  DOI：

  10.1021/acs.jmedchem.6b00275

文献信息

• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
  申请人：Diaz Caroline Jean

  公开号：US20100222345A1

  公开（公告）日：2010-09-02

  This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

  这项发明涉及新型化合物，它们是阿片受体的拮抗剂或逆向激动剂之一，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗中的应用。
• BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：Bloxham Jason

  公开号：US20100173886A1

  公开（公告）日：2010-07-08

  Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.

  化合物式(I)或其药学上可接受的盐，是阿片受体调节剂，例如μ-阿片受体拮抗剂，中性拮抗剂或倒向激动剂，并且可用于治疗代谢性疾病，包括肥胖症。
• US8278442B2
  申请人：——

  公开号：US8278442B2

  公开（公告）日：2012-10-02
• [EN] NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS<br/>[FR] NOUVEAUX COMPOSÉS COMME ANTAGONISTES OU AGONISTES INVERSES POUR LES RÉCEPTEURS D'OPIOÏDES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2008021851A2

  公开（公告）日：2008-02-21

  [EN] This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
  [FR] Cette invention concerne de nouveaux composés qui sont des antagonistes ou des agonistes inverses à un ou à plusieurs récepteurs d'opioïdes, des compositions pharmaceutiques contenant lesdits composés, des procédés permettant de les préparer, et leur utilisation en thérapie.
• [EN] BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] COMPOSÉS D'ARYLE ET D'HÉTÉROARYLE BICYCLIQUES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：PROSIDION LTD

  公开号：WO2008142454A1

  公开（公告）日：2008-11-27

  [EN] Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu- opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.
  [FR] L'invention concerne des composés de formule (I) : ou des sels pharmaceutiquement acceptables de ceux-ci, qui sont des modulateurs des récepteurs opioïdes, par exemple, des antagonistes des récepteurs mu-opioïdes, des antagonistes neutres ou des agonistes inverses, et qui sont utiles pour le traitement de troubles métaboliques comprenant l'obésité.